Analyzing Lexaria Bioscience (NASDAQ:LEXX) & GlobeImmune (OTCMKTS:GBIM)

Lexaria Bioscience (NASDAQ:LEXX) and GlobeImmune (OTCMKTS:GBIM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Profitability

This table compares Lexaria Bioscience and GlobeImmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	-1,473.04%	-88.88%	-83.59%
GlobeImmune	N/A	N/A	N/A

Earnings & Valuation

This table compares Lexaria Bioscience and GlobeImmune”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$525,923.00	36.06	-$5.80 million	($0.59)	-1.83
GlobeImmune	N/A	N/A	N/A	N/A	N/A

GlobeImmune has lower revenue, but higher earnings than Lexaria Bioscience.

Institutional and Insider Ownership

13.1% of Lexaria Bioscience shares are owned by institutional investors. 26.4% of Lexaria Bioscience shares are owned by insiders. Comparatively, 23.5% of GlobeImmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Lexaria Bioscience has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, GlobeImmune has a beta of -208.98, indicating that its share price is 20,998% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Lexaria Bioscience and GlobeImmune, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	0	0	1	0	3.00
GlobeImmune	0	0	0	0	0.00

Lexaria Bioscience currently has a consensus target price of $7.00, indicating a potential upside of 548.15%. Given Lexaria Bioscience’s stronger consensus rating and higher probable upside, research analysts plainly believe Lexaria Bioscience is more favorable than GlobeImmune.

Summary

Lexaria Bioscience beats GlobeImmune on 7 of the 10 factors compared between the two stocks.

About Lexaria Bioscience

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

About GlobeImmune

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. operates as a subsidiary of ImmunityBio, Inc.